

1. **What is the EPO Case Number of the EISAI case in which Swiss-type claims were first adopted by the EPO?**
 - a. G5/83
 - b. G6/84
 - c. G7/83

2. **What was unusual about the composition of the English Patents Court in the John Wyeth case in 1985?**
 - a. The Judge who heard the case was not a patent specialist
 - b. A Court of Appeal Judge was assigned to hear the case due to its importance
 - c. The English Patents Court sat *en banc*

3. **What is the correct term for manifest preparation in German?**
 - a. hinfallige Herrichtung
 - b. sinnfallige Herrichtung
 - c. hinfallige Vorrichtung

4. **What is T1780/12 most famous for?**
 - a. The TBA held that Swiss-type claims were no longer to be permitted by the EPO
 - b. The TBA held that a double-patenting objection did not arise as between Swiss-type claims and EPC 2000 claims
 - c. The TBA held that dosage regimens were as a matter of principle not objectionable under the EPC

5. **When is the UK Supreme Court scheduled to hear the appeal in the pemetrexed case?**
 - a. March 2017
 - b. April 2017
 - c. No date has yet been fixed

6. **In which city was AIPPI Resolution 238 (on second medical use patents) passed?**
 - a. Hyderabad
 - b. Helsinki
 - c. Toronto

7. **Which Court issued the decision in the Lyrica patent infringement preliminary injunction proceedings in Germany?**
 - a. Duesseldorf Regional Court

- b. Hamburg Regional Court
 - c. the Bundesgerichtshof
8. True or False, in October 2015 Pfizer was successful in obtaining a preliminary injunction against Sandoz following launch of its carved out pregabalin medicine in France?
9. What was the composition of the Dutch Court of Appeal in the Novartis v Sun case which adjudged Sun to have indirectly infringed Novartis dosage regimen patent for zoledronic acid in the treatment of osteoporosis?
- a. Blok, Kiers-Becking and Bonneur
 - b. Kalden, Pinckaers and Van der Burg
 - c. Kalden, Brinkman and Van Nispen
10. How many defendants were there to the Danish action brought by Warner-Lambert and Pfizer in relation to Krka's generic pregabalin in 2015?
- a. 2
 - b. 22
 - c. 220
11. In your opinion, what is the best analysis of the construction of Swiss-type claims?
- a. They should be construed as purpose-limited product claims
 - b. They should be construed as purpose-limited process claims and the manufacturing step is the cornerstone of the claim
 - c. They should be construed as purpose-limited process claims but the scope of the claim extends from the manufacture of the API through to the ascribing of the indication for which the medicine is to be used
 - d. They should be construed as method of treatment claims.
12. In your opinion, what should generics companies have to do in order to ensure that their product is not used for the patented indication?
- a. Nothing – it's up to the patentee to ensure its patent is respected
 - b. Carve out the patented indication from its label and no more
 - c. Carve out the patented indication from its label and not promote its product for the patented purpose
 - d. Actively engage with the patentee and other stake-holders to minimise cross-label use?
 - e. None of the above